Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\textquoterights disease

Keywords : CRTI Team4
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/hal-01881123
Contributor : Nicolas Degauque <>
Submitted on : Tuesday, September 25, 2018 - 2:52:12 PM
Last modification on : Friday, October 18, 2019 - 10:46:02 AM

Links full text

Identifiers

Citation

Cem Gabay, Bruno Fautrel, Jürgen Rech, François Spertini, Eugen Feist, et al.. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\textquoterights disease. Annals of the Rheumatic Diseases, BMJ Publishing Group, 2018, 13, pp.annrheumdis--2017--212608. ⟨10.1136/annrheumdis-2017-212608⟩. ⟨hal-01881123⟩

Share

Metrics

Record views

55